A Study to Assess AXN-2510 Treatment in Adult Patients With Advanced Solid Tumors

计划入组 3 人 · 首次发布于 2025 年 9 月 8 日

IMM2510, a PD-L1 and VEGF Bispecific Fusion Protein, in Patients With Advanced Solid Tumors

计划入组 108 人 · 首次发布于 2023 年 8 月 2 日

A Study of IMM2510 + IMM27M Combination Therapy in Patients With Advanced Solid Tumors

计划入组 108 人 · 首次发布于 2025 年 1 月 8 日

IMM-2510

AXN-1901

AXON NEUROSCIENCE SE

Cyprus

Anx Robotica Corp

United States

AIN SHAMS UNIVERSITY

Egypt

Instil Bio's PD-L1xVEGF Bispecific Antibody Shows Promise in NSCLC, Driving 48% Stock Surge

Instil Bio and ImmuneOnco Advance PD-(L)1xVEGF Bispecific Antibody Clinical Development Strategy

Instil Bio's Partner ImmuneOnco Doses First Patient in NSCLC Trial with IMM2510/SYN-2510